Online inquiry

IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14980MR)

This product GTTS-WQ14980MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Diseases or disorders including airway inflammation research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ14980MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2756MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG162
GTTS-WQ1939MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ5036MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ1831MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ6899MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ8005MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GZ-402668
GTTS-WQ6402MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ14700MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SEG101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW